Protein mutagenesis with monodispersity-based quality probing: Selective inactivation of p53 degradation and DNA-binding properties of HPV E6 oncoprotein

Protein Expression and Purification

Volumn 26, Issue 3, 2002, Pages 357-367

  Ristriani, Tutik ^a   Nominé, Yves ^a   Laurent, Cécile ^a   Weiss, Étienne ^a   Travé, Gilles ^a  

^a CNRS   (France)

Author keywords

Discriminating mutagenesis; DNA recognition; HPV oncoprotein E6; p53 degradation; Protein fusion quality; Structure integrity

Indexed keywords

AMINO ACID SEQUENCE; CARRIER PROTEINS; DNA; DNA-BINDING PROTEINS; MOLECULAR SEQUENCE DATA; MUTATION; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; PROTEIN DENATURATION; RECOMBINANT FUSION PROTEINS; SOLUBILITY; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0036910526     PISSN: 10465928     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1046-5928(02)00570-3     Document Type: Article

References (45)

1. H. zur Hausen, Human papillomaviruses in the pathogenesis of anogenital cancer, Virology 184 (1991) 9-13.
2. S.T. Cole, O. Danos, Nucleotide sequence and comparative analysis of the human papillomavirus type 18 genome. Phylogeny of papillomaviruses and repeated structure of the E6 and E7 gene products, J. Mol. Biol. 193 (4) (1987) 599-608.
3. S.R. Grossman, L.A. Laimins, E6 protein of human papillomavirus type 18 binds zinc, Oncogene 4 (9) (1989) 1089-1093.
4. M.S. Barbosa, D.R. Lowy, J.T. Schiller, Papillomavirus polypeptides E6 and E7 are zinc-binding proteins, J. Virol. 63 (3) (1989) 1404-1407.
5. M.S. Barbosa, D.R. Lowy, J.T. Schiller, Papillomavirus E6 and E7 are zinc-binding proteins, J. Virol. 63 (1989) 1404-1407.
6. 2+-binding fragment from the human papillomavirus type 16 E6 protein, Biochemistry 40 (5) (2001) 1196-1204.
7. M. Scheffner, B.A. Werness, J.M. Huibregtse, A.J. Levine, P.M. Howley, The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53, Cell 63 (1990) 1129-1136.
8. M. Scheffner, J.M. Huibregtse, R.D. Vierstra, P.M. Howley, The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53, Cell 75 (1993) 495-505.
9. J. Chen, C.E. Reid, V. Band, E.J. Androphy, Interaction of papillomavirus E6 proteins with a putative calcium binding protein, Science 269 (1995) 529-532.
10. T. Kiyono, A. Hiraiwa, M. Fujita, Y. Hayashi, T. Akiyama, M. Ishibashi, Binding of high-risk human papillomavirus E6 oncoproteins to the human homologue of the Drosophila discs large tumor suppressor protein, Proc. Natl. Acad. Sci. USA 94 (21) (1997) 11612-11616.
11. X. Tong, P.M. Howley, The bovine papillomavirus E6 oncoprotein interacts with paxillin and disrupts the actin cytoskeleton, Proc. Natl. Acad. Sci. USA 94 (9) (1997) 4412-4417.
12. S.B. Vande Pol, M.C. Brown, C.E. Turner, Association of bovine papillomavirus type 1 E6 oncoprotein with the focal adhesion protein paxillin through a conserved protein interaction motif, Oncogene 16 (1) (1998) 43-52.
13. L.V. Ronco, A.Y. Karpova, M. Vidal, P.M. Howley, Human papillomavirus 16 E6 oncoprotein binds to interferon regulatory factor-3 and inhibits its transcriptional activity, Genes Dev. 12 (1998) 2061-2072.
14. X. Tong, W. Boll, T. Kirchhausen, P.M. Howley, Interaction of the bovine papillomavirus E6 protein with the clathrin adaptor complex AP-1, J. Virol. 72 (1) (1998) 476-482.
15. I. Kukimoto, S. Aihara, K. Yoshiike, T. Kanda, Human papillomavirus E6 protein binds to the C-terminal region of human minichromosome maintenance 7 protein, Biochem. Biophys. Res. Commun. 249 (1998) 258-262.
16. D. Patel, S.M. Huang, L.A. Baglia, D.J. McCance, The E6 protein of human papillomavirus type 16 binds to and inhibits co-activation by CBP and p300, EMBO J. 18 (1999) 5061-5072.
17. H. Zimmermann, R. Degenkolbe, H.U. Bernard, M.J. O'Connor, The human papillomavirus type 16 E6 oncoprotein can down-regulate p53 activity by targeting the transcriptional coactivator CBP/p300, J. Virol. 73 (1999) 6209-6219.
18. M. Thomas, L. Banks, Inhibition of Bak-induced apoptosis by HPV-18 E6, Oncogene 17 (1998) 2943-2954.
19. M. Thomas, L. Banks, Human papillomavirus (HPV) E6 interactions with Bak are conserved amongst E6 proteins from high and low risk HPV types, Gen. Virol. 80 (1999) 1513-1517.
20. Q. Gao, S. Srinivasan, S.N. Boyer, D.E. Wazer, V. Band, The E6 oncoproteins of high-risk papillomaviruses bind to a novel putative GAP protein, E6TP1, and target it for degradation, Mol. Cell. Biol. 19 (1999) 733-744.
21. S. Li, S. Labrecque, M.C. Gauzzi, A.R. Cuddihy, A.H. Wong, S. Pellegrini, G.J. Matlashewski, A.E. Koromilas, The human papilloma virus (HPV)-18 E6 oncoprotein physically associates with Tyk2 and impairs Jak-STAT activation by interferon-α, Oncogene 18 (42) (1999) 5727-5737.
22. S. Nakagawa, J.M. Huibregtse, Human scribble (Vartul) is targeted for ubiquitin-mediated degradation by the high-risk papillomavirus E6 proteins and the E6AP ubiquitin-protein ligase, Mol. Cell. Biol. 20 (21) (2000) 8244-8253.
23. S.A. Sedman, M.S. Barbosa, W.C. Vaa, N.L. Hubbert, J.A. Haas, D.R. Lowy, J.T. Schiller, The full-length E6 protein of human papillomavirus type 16 has transforming and transactivating activities and cooperates with E7 to immortalize keratinocytes in culture, J. Virol. 65 (1991) 4860-4866.
24. A. Morosow, W.C. Phelps, P. Raychaudhuri, Activation of c-fos gene by the HPV16 oncoproteine depends upon the cAMP-response element at -60, J. Biol. Chem. 269 (1994) 18434-18440.
25. A. Dey, I.A. Atcha, S. Bagchi, HPV16 E6 oncoprotein stimulates the transforming growth factor-β 1 promoter in fibroblasts through a specific GC-rich sequence, Virology 228 (2) (1997) 190-199.
26. L. Gewin, D.A. Galloway, E box-dependent activation of telomerase by human papillomavirus type 16 E6 does not require induction of c-myc, J. Virol. 75 (15) (2001) 7198-7201.
27. T. Veldman, I. Horikawa, J.C. Barrett, R. Schlegel, Transcriptional activation of the telomerase hTERT gene by human papillomavirus type 16 E6 oncoprotein, J. Virol. 75 (9) (2001) 4467-4472.
28. S.T. Oh, S. Kyo, L.A. Laimins, Telomerase activation by human papillomavirus type 16 E6 protein: Induction of human telomerase reverse transcriptase expression through Myc and GC-rich Sp1 binding sites, J. Virol. 75 (12) (2001) 5559-5566.
29. T. Ristriani, M. Masson, Y. Nominé, C. Laurent, J.F. Lefèvre, E. Weiss, G. Travé, HPV oncoprotein E6 is a structure-dependent DNA-binding protein that recognizes four-way junctions, J. Mol. Biol. 296 (5) (2000) 1189-1203.
30. T. Ristriani, Y. Nomine, M. Masson, E. Weiss, G. Trave, Specific recognition of four-way DNA junctions by the C-terminal zinc-binding domain of HPV oncoprotein E6, J. Mol. Biol. 305 (4) (2001) 729-739.
31. T. Crook, J.A. Tidy, K.H. Vousden, Degradation of p53 can be targeted by HPV E6 sequences distinct from those required for p53 binding and trans-activation, Cell 67 (3) (1991) 547-556.
32. D. Pim, A. Storey, M. Thomas, P. Massimi, L. Banks, Mutational analysis of HPV-18 E6 identifies domains required for p53 degradation in vitro, abolition of p53 transactivation in vivo and immortalisation of primary BMK cells, Oncogene 9 (7) (1994) 1869-1876.
33. S. Nakagawa, S. Watanabe, H. Yoshikawa, Y. Taketani, K. Yoshiike, T. Kanda, Mutational analysis of human papillomavirus type 16 E6 protein: Transforming function for human cells and degradation of p53 in vitro, Virology 212 (2) (1995) 535-542.
34. Y. Nominé, T. Ristriani, C. Laurent, J.F. Lefèvre, E. Weiss, G. Travé, Formation of soluble inclusion bodies by HPV E6 oncoprotein fused to Maltose-binding protein, Protein Expr. Purif. 23 (1) (2001) 22-32.
35. Y. Nominé, T. Ristriani, C. Laurent, J.F. Lefèvre, E. Weiss, G. Travé, A strategy for optimizing the monodispersity of fusion proteins: Application to purification of recombinant HPV E6 oncoprotein, Protein Eng. 14 (4) (2001) 297-305.
36. D.R. Duckett, A.I.H. Murchie, S. Diekmann, E. Von Kitzing, B. Kemper, D.M.J. Lilley, The structure of the Holliday Junction, and its resolution, Cell 55 (1988) 79-89.
37. C. Giovane, G. Trave, A. Briones, Y. Lutz, B. Wasylyk, E. Weiss, Targetting of the N-terminal domain of the human papillomavirus type 16 E6 oncoprotein with monomeric ScFvs blockes the E6-mediated degradation of cellular p53, J. Mol. Recogn. 12 (1999) 141-152.
38. M. Kunitani, S. Wolfe, S. Rana, C. Apicella, V. Levi, G. Dollinger, Classical light scattering quantitation of protein aggregates: Off-line spectroscopy versus HPLC detection, J. Pharm. Biomed. Anal. 16 (4) (1997) 573-586.
39. E.J. Androphy, N.L. Hubbert, J.T. Schiller, D.R. Lowy, Identification of the HPV-16 E6 protein from transformed mouse cells in human cervical carcinoma cell lines, EMBO J. 6 (1987) 989-992.
40. S.A. Foster, G.W. Demers, B.G. Etscheid, D.A. Galloway, The ability of human papillomavirus E6 proteins to target p53 for degradation in vivo correlates with their ability to abrogate actinomycin D-induced growth arrest, J. Virol. 68 (1994) 5698-5705.
41. Q. Gao, L. Singh, A. Kumar, S. Srinivasan, D.E. Wazer, V. Band, Human papillomavirus type 16 E6-induced degradation of E6TP1 correlates with its ability to immortalize human mammary epithelial cells, J. Virol. 75 (9) (2001) 4459-4466.
42. R.J. Slebos, T.D. Kessis, A.W. Chen, S.M. Han, L. Hedrick, K.R. Cho, Functional consequences of directed mutations in human papillomavirus E6 proteins: Abrogation of p53-mediated cell cycle arrest correlates with p53 binding and degradation in vitro, Virology 208 (1995) 111-120.
43. M. Elbel, S. Carl, S. Spaderna, T. Iftner, A comparative analysis of the interactions of the E6 proteins from cutaneous and genital papillomaviruses with p53 and E6AP in correlation to their transforming potential, Virology 239 (1) (1997) 132-149.
44. S. Dalal, Q. Gao, E.J. Androphy, V. Band, Mutational analysis of human papillomavirus type 16 E6 demonstrates that p53 degradation is necessary for immortalization of mammary epithelial cells, J. Virol. 70 (2) (1996) 683-688.
45. D. Gardiol, L. Banks, Comparison of human papillomavirus type 18 (HPV-18) E6-mediated degradation of p53 in vitro and in vivo reveals significant differences based on p53 structure and cell type but little difference with respect to mutants of HPV-18 E6, J. Gen. Virol. 79 (1998) 1963-1970.